TY - JOUR ID - 30190 TI - Drug Resistance Effects of Ribosomal Protein L24 Overexpression in Hepatocellular Carcinoma HepG2 Cells JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 Y1 - 2014 PY - 2014 VL - 15 IS - 22 SP - 9853 EP - 9857 KW - Ribosomal protein L24 KW - drug resistance mechanism KW - Liver cancer KW - HepG2 cells DO - N2 - Background: The morbidity and mortality rate of liver cancer continues to rise in China and advanced casesrespond poorly to chemotherapy. Ribosomal protein L24 has been reported to be a potential therapeutic targetwhose depletion or acetylation inhibits polysome assembly and cell growth of cancer. Materials and Methods:Total RNA of cultured amycin-resistant and susceptible HepG2 cells was isolated, and real time quantitativeRT-PCR were used to indicate differences between amycin-resistant and susceptible strains of HepG2 cells.Viability assays were used to determine amycin resistance in RPL24 transfected and control vector and nulltransfectedHepG2 cell lines. Results: The ribosomal protein L24 transcription level was 7.7 times higher inthe drug-resistant HepG2 cells as compared to susceptible cells on quantitative RT-PCR analysis. This wasassociated with enhanced drug resistance as determined by methyl tritiated thymidine (3H-TdR) incorporation.Conclusions: The ribosomal protein L24 gene may have effects on drug resistance mechanisms in hepatocellularcarcinoma HepG2 cells. UR - https://journal.waocp.org/article_30190.html L1 - https://journal.waocp.org/article_30190_61c53d9e0e4f8f9a7584b239042f21c9.pdf ER -